Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

Video

In Partnership With:

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Joshua Richter, MD, an assistant professor of medicine, and a hematologist/oncologist at Mount Sinai Hospital, discusses the importance of optimizing available therapies in multiple myeloma. 

Historically, multiple myeloma was thought to be an incurable disease, says Richter. ​However, ​multiple advances in the field have pushed the field closer to developing a cure for patients.  

In addition to conducting more clinical trials and evaluating novel regimens, it is necessary to optimize available therapies, Richter adds. 

Utilizing a multiomic approach may allow the field to optimize existing approaches, ​and provide precision medicine to patients with multiple myeloma, Richter concludes. 

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD